Neurodevelopmental Intervention for Preterm Infants
Trial Summary
What is the purpose of this trial?
NeuroN-QI aims to evaluate the effects of an intervention consisting of periods of: 1) parents/preterm infants skin-to-skin contact and auditory stimulation by the parents's voice and 2) calm without manipulation with olfactory stimulation with breast milk in the incubator/bed both combined with appropriate light and noise levels to promote neurodevelopment preterm infants.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, infants still receiving certain medications like analgesics (pain relievers), sedatives, or paralyzing agents are excluded from the trial.
What data supports the effectiveness of the treatment NeuroN-QI, Nurturing and Quiet Intervention, SSC alone, Kangaroo Care, Skin-to-Skin Contact for preterm infants?
Research shows that Kangaroo Care, which involves skin-to-skin contact, can improve early cognitive development, neuromotor skills, and neurobehavioral performance in preterm infants. It also helps with stress response and breastfeeding success, indicating its positive impact on growth and development.12345
Is Kangaroo Care safe for preterm infants?
How is the NeuroN-QI treatment different from other treatments for preterm infants?
NeuroN-QI, which includes Kangaroo Care (skin-to-skin contact), is unique because it emphasizes direct physical contact between the parent and infant, which has been shown to support early cognitive and neuromotor development in preterm infants. This approach is different from traditional care methods that may not involve as much parental involvement or sensory stimulation.1291011
Eligibility Criteria
This trial is for preterm infants born between 24 and nearly 34 weeks of gestational age, who are stable enough for skin-to-skin contact (SSC). Parents must commit to at least one SSC session per week with auditory stimulation until the infant reaches 36 weeks of gestational age. Mothers should be expressing breast milk for their infants. In case of twins, fathers can also participate.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Parents and preterm infants engage in skin-to-skin contact and auditory stimulation, followed by a calm period with olfactory stimulation, until the infants reach 36 weeks gestational age.
Follow-up
Participants are monitored for neurodevelopmental outcomes and parental stress and anxiety levels.
Treatment Details
Interventions
- NeuroN-QI
- SSC alone
Find a Clinic Near You
Who Is Running the Clinical Trial?
St. Justine's Hospital
Lead Sponsor